

V. Hurez¹, M. Weis¹, R. Baillie¹, M. Rehberg², K. Beuke², N. Biesemann³, C. Asbrand³, T. Klabunde², M. Herrmann³, M. Reed^{1*}

¹Rosa & Co., LLC., San Carlos, CA, USA; ²Sanofi R&D Translational Informatics, Frankfurt, Germany; ³Sanofi R&D Immunology and Inflammation Therapeutic Area, Frankfurt, Germany. *mreed@rosaandco.com

Introduction

- RA is a common autoimmune disease associated with progressive disability, systemic complications, early death, and socioeconomic costs.
- RA is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage and bone destruction, and systemic features.
- Anti-TNF α , anti-IL-6, and anti-IL-6 receptor (IL-6R) therapies are approved for use in RA.
- A significant number of patients do not respond to treatment. Therefore, the development of new treatment approaches is warranted.

Objectives

- Support the development of novel anti-TNF α and IL-6R therapies for RA
- Gain a deeper understanding of the key biological pathways impacting clinical response to anti-TNF α or anti-IL-6R
- Identify RA patient phenotypes with optimal response to therapy

Methods

PhysioPD™ Research Platforms are mechanistic, QSP models that allow investigation of the connection between mechanisms and outcomes.

- Rosa and Sanofi developed a QSP model of RA, the RA PhysioPD Platform, using engineering approaches and scientific data analysis to clarify complex physiology and drug mechanism of action
- The RA Platform was qualified in accordance with Rosa's Model Qualification Method¹ (MQM) (Figure 1)
- The RA Platform represents mechanistically the physiology of a single RA joint (Figure 2) including:
 - Fibroblast-like synoviocytes (FLS), immune cells, cytokines, chemokines, and their regulation
 - Standard therapies (adalimumab, sarilumab, sirukumab, methotrexate [MTX], baricitinib)
 - Clinical outcomes (DAS28-CRP score)




Figure 1. Rosa's Model Qualification Method¹ (MQM)

RA PhysioPD Platform Overview




Figure 2. RA Platform developed in Simbiology²

References

- Friedrich CM. CPT: pharmacometrics & systems pharmacology. 2016;5(2):43-53.
- Schmidt H, Jirstrand M. Bioinformatics. 2006;22(4):514-5.
- Smeets TJ, Kraan MC, van Loon ME, Tak PP. Arthritis and rheumatism. 2003;48(8):2155-62.

Platform Qualification

The reference virtual patient (VP) is representative of an average moderate/severe MTX-inadequate responder RA patient with stable, chronic disease

- Cell numbers in blood and synovium were calibrated to match the average from several published studies for moderate/severe RA patients (Figure 3)
- Synovial mediator levels, determined by clearance rates, cell numbers, and cell-type specific production rates also matched reported literature averages




Figure 3. Blood cell concentrations (left) and synovial cell densities (right) in untreated reference VP. Baseline Platform calibration represents a dynamic equilibrium that reflects stable, chronic disease. Data values are plotted at arbitrary time points.

Serial histological studies from biopsies of patients were used to qualify cellular responses to therapies




Figure 4. Reduction in synovial FLS, macrophages, CD4+ T cells and B cells in anti-TNF α treated reference VP. Simulations (pink line) of 40 mg Q2W adalimumab treatment in reference VP compared to published data (ϕ : mean \pm SD)

Reference VP response matches average clinical response to anti-TNF α and anti-IL-6R measured in large clinical trials




Figure 5. Reduction in DAS28-CRP in reference VP treated with anti-TNF α or anti-IL-6R (left) or anti-IL-6R + MTX (right). Simulations in reference VP (dashed lines) of 40 mg Q2W adalimumab, 200 mg sarilumab Q2W or 150 mg sarilumab Q2W + MTX vs. clinical score from the MONARCH (Burmester et al. 2017) and MOBILITY trials (Genovese et al. 2015) (ϕ : mean \pm SD)

Reference VP has an average clinical response to all implemented test therapies in combination with MTX




Figure 6. Reduction in DAS28-CRP in reference VP treated MTX and anti-IL-6 (left) or the JAK inhibitor baricitinib (right). Simulations in reference VP (pink line) of 100 mg sirukumab Q2W or 4 mg baricitinib QD in reference VP on a MTX-background treatment compared to published data (ϕ : mean \pm SD)

- Izquierdo E, Canete JD, Celis R, Santiago B, Usategui A, Sanmarti R, et al. PLoS One. 2009;4(12):e8131.
- Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, et al. Rheumatology (Oxford). 2002;41(5):484-9.
- Kanbe K, Chiba J, Nakamura A. Rheumatol Int. 2014;34(1):125-30.
- Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. Ann Rheum Dis. 2017;76(5):840-7.
- Genovese MC, Fleischmann R, Kivitz AJ, Reil-Bakalarska M, Martinova R, Fiore S, et al. Arthritis & rheumatology (Hoboken, NJ). 2015;67(6):1424-37.
- Taylor PC, Schiff MH, Wang Q, Jiang Y, Zhuang Y, Kurrasch R, et al. Ann Rheum Dis. 2018.
- Takeuchi T, Tanaka Y, Yamanaka H, Harigai M, Nakano T, Akagi K, et al. Modern rheumatology. 2018;1-9.
- Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Ann Rheum Dis. 2017;76(1):88-95.
- Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes-Gonzaga J, et al. New England Journal of medicine. 2017;376(7):652-62.
- Dennis G, Jr., Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, et al. Arthritis research & therapy. 2014;16(2):R90.

Alternate Virtual patients

Specific RA synovial phenotypes have differential response to anti-TNF α vs. anti-IL-6R therapies

- Dennis et al. 2014 identified phenotypes which may predict response to anti-TNF α and anti-IL-6R therapies (Table 1)

Table 1. Characteristics of the four major phenotypes of RA synovium identified

| Phenotype | Lymphoid | Myeloid | Low inflammation | Fibroid |
|--|--|---|--|---|
| Defining gene clusters (microarrays) | B and/or T lymphocyte activation and differentiation, Ig production, IL-17 signaling | chemotaxis, TNF α and IL-1 β production, phagocytosis, mononuclear cells proliferation | inflammatory response and wound response processes | TGF β & bone morphogenetic protein signaling, endocytosis |
| Synovial cell infiltration (histology, FACS) | T cells: ++ B cells: +++ Mac.: +++ Fibroblasts: + | T cells: +++ B cells: + Mac.: +++ Fibroblasts: ++ | T cells: ++ B cells: - Mac.: ++ Fibroblasts: ++ | T cells: ++ B cells: - Mac.: ++ Fibroblasts: +++ |
| Serum biomarkers | sICAM: low CXCL13: high | sICAM: high CXCL13: med | sICAM: low CXCL13: med | sICAM: low CXCL13: low |

Four alternate VPs with diverse phenotypes were created to explore response to anti-TNF α and anti-IL-6R therapies

Table 2. Characteristics of the different VP phenotypes created and their relative response to therapies

| VP phenotype | Response to therapy | | |
|-----------------|---------------------|-------------------|------------|
| | MTX | Anti-TNF α | Anti-IL-6R |
| Reference VP | \pm | ++ | +++ |
| Anti-TNF-IR #1* | \pm | ++ | +++ |
| Anti-TNF-IR #2 | \pm | \pm | +++ |
| Anti-IL-6-IR #1 | \pm | +++ | + |

* IR: inadequate-responder

The alternate VPs cover a range of responses to the various therapies




Figure 8. Clinical response of the five VPs to anti-TNF α , anti-IL-6R and anti-IL-6 therapies with or without MTX. % change in DAS28-CRP at 24 weeks in all VPs treated with adalimumab, sarilumab or sirukumab alone (left) or with MTX (right)

Sensitivity analysis highlights the role of IL-6 as a major driver of RA pathophysiology

- A sensitivity analysis of the untreated reference VP was performed by modifying each parameter by \pm 10% and measuring the impact after 52 weeks

- The most sensitive pathways for baseline DAS28-CRP (as a measure of disease severity) were:
 - Cytokine regulation of B cell & FLS clearance
 - Macrophage recruitment and clearance
 - Treg proliferation and clearance
 - TNF α and other proinflammatory cytokines




Figure 9. Analysis of the most-sensitive pathways for DAS28-CRP in the untreated reference VP. Ranking of the 30 most-sensitive pathways affecting baseline DAS28-CRP levels. The bars are color-coded to identify parameters regulating a specific cell type (see legend) or mediator (Other, in dark red)

Conclusions

- Anti-TNF α inadequate responders could benefit from switching to novel anti-TNF α or anti-IL-6R therapies, in particular in patients developing anti-drug antibodies
- IL-6 pathways are key disease drivers in a majority of the VPs phenotypes resulting in more patients responding to anti-IL-6R than to anti-TNF α therapies

For more information about this work, please contact:

Mike Reed
Rosa & Co LLC
(650) 393-3738
mreed@rosaandco.com